FDA Approves Clinical Trial for Cancer-Busting Turkey Tail Mushroom

In what may be the most significant health discovery for mycologists and health researchers since the invention of penicillin (which was derived from the fungus Penicillium), research continues to mount as to the amazing healing effects of Turkey Tail mushroom against Breast Cancer.

News about Turkey Tail

The news about Turkey Tail made headlines in 2012 when the FDA approved clinical trials to test the cancer-healing properties of Polysaccharide K (PSK), an extract that comes from Trametes versicolor, or Turkey Tail mushroom. Turkey Tail has been used medicinally all over Asia for thousands of years, usually in tea form. As of 2014, the clinical trial, sponsored by Bastyr University and head researchers Cynthia Wenner PhD and Masa Sasagawa, ND, was in Phase I/II with women who have Stage IV breast cancer.

One of the first study reports that Bastyr University researchers published, along with their partners from the University of Minnesota Medical School, showed that the Turkey Tail extract (PSK) was successful at restoring the immune systems and improving the health of women who had undergone traditional cancer therapy (radiation in particular). The study found that Turkey Tail mushroom extract was able to increase the level and activity of Natural Killer Cells as well as “cytotoxic T-cells.”

The job of NK cells in the body is to hunt down harmful pathogens, especially cancer cells, and destroy them. All the women in this part of the trial had raised lymphocyte as well as NK cell counts after a daily dose of 6 and 9 grams over a period of 4 weeks. Those women who were given the higher amounts (9 grams) showed higher levels of T cells. No negative side effects were discovered with any of the women.

Noted Researchers Speak Out About Turkey Tail

Famed mycologist and author Paul Stamets, whose mother healed from breast cancer with the use of Turkey Tail in 2009, has been one of the main providers of Turkey Tail mushrooms and has also served as director of research for many past studies.

“Cancer is notorious for its ability to evade immune detection,” says Stamets. “One theory is that when patients ingest our Turkey Tail mycelium, the immune system’s increased populations of NK cells and their associated CD8 glycoproteins are better able to discover and bind to receptor sites on the stroma of tumors, thus allowing NK invasion.”

Dr. Wenner of Bastyr University recently spoke about their findings to a group of over 100 clinical oncologists in Tokyo.

“The opportunity to present our findings to an international audience is quite important,” Dr. Wenner said in a statement. “Having worked as an investigator on the study since 2004, it felt like a fitting conclusion to bring back these positive findings to a group that has access to this mushroom extract and can apply our findings to treatment options in their oncology practices and in doing further research.”

FDA Approval Still Stalled

In previous studies, Turkey Tail has also been shown to help with upper respiratory tract infections, pulmonary disease, urinary tract infections, malaise and digestive tract issues. And it has shown to be effective against colorectal cancer and lymphoma.

PSK/ Turkey Tail extract is still not approved for medical use in the U.S. but perhaps the final results of the Bastyr University study, combined with the results of all the other Turkey Tail mushroom studies over the years, will finally push the envelope towards approval soon.

One thing is for sure: the positive evidence demonstrated so far by the Bastyr study as to how Turkey Tail has helped reinvigorate the immune systems of Stage IV Breast Cancer patients proves that with a little help from Nature, the body can– and does– heal from cancer.

Dr. Veronique Desaulniers, better known as Dr. V, is the founder of  The 7 Essentials System ™, a step-by-step guide that teaches you exactly how to prevent and heal Breast Cancer naturally. To get your FREE 7-Day Mini e-Course and to receive her weekly action steps and inspiring articles on the power of Natural Medicine, visit her at BreastCancerConqueror.com

FDA Approves Clinical Trial for Cancer-Busting Turkey Tail Mushroom

Magic mushroom ingredient psilocybin can lift depression, studies show

A single dose of psilocybin, the active ingredient of magic mushrooms, can lift the anxiety and depression experienced by people with advanced cancer for six months or even longer, two new studies show.

Researchers involved in the two trials in the United States say the results are remarkable. The volunteers had “profoundly meaningful and spiritual experiences” which made most of them rethink life and death, ended their despair and brought about lasting improvement in the quality of their lives.

The results of the research are published in the Journal of Psychopharmacology together with no less than ten commentaries from leading scientists in the fields of psychiatry and palliative care, who all back further research. While the effects of magic mushrooms have been of interest to psychiatry since the 1950s, the classification of all psychedelics in the US as schedule 1 drugs in the 1970s, in the wake of the Vietnam war and the rise of recreational drug use in the hippy counter-culture, has erected daunting legal and financial obstacles to running trials.

“I think it is a big deal both in terms of the findings and in terms of the history and what it represents. It was part of psychiatry and vanished and now it’s been brought back,” said Dr Stephen Ross, director of addiction psychiatry at NYU Langone Medical Center and lead investigator of the study that was based there.

Around 40-50% of newly diagnosed cancer patients suffer some sort of depression or anxiety. Antidepressants have little effect, particularly on the “existential” depression that can lead some to feel their lives are meaningless and contemplate suicide.

The main findings of the NYU study, which involved 29 patients, and the larger one from Johns Hopkins University with 51 patients, that a single dose of the medication can lead to immediate reduction in the depression and anxiety caused by cancer and that the effect can last up to eight months, “is unprecedented,” said Ross. “We don’t have anything like it.”

The results of the studies were very similar, with around 80% of the patients attributing moderately or greatly improved wellbeing or life satisfaction to a single high dose of the drug, given with psychotherapy support.

Professor Roland Griffiths, of the departments of psychiatry and neuroscience who led the study at Johns Hopkins University school of medicine, said he did not expect the findings, which he described as remarkable. “I am bred as a sceptic. I was sceptical at the outset that this drug could produce long-lasting changes,” he said. These were people “facing the deepest existential questions that humans can encounter – what is the nature of life and death, the meaning of life.”

But the results were similar to those they had found in earlier studies in healthy volunteers. “In spite of their unique vulnerability and the mood disruption that the illness and contemplation of their death has prompted, these participants have the same kind of experiences, that are deeply meaningful, spiritually significant and producing enduring positive changes in life and mood and behaviour,” he said.

Patients describe the experiences as “re-organisational”, said Griffiths. Some in the field had used the term “mystical”, which he thought was unfortunate. “It sounds unscientific. It sounds like we’re postulating mechanisms other than neuroscience and I’m certainly not making that claim.”

Ross said psilocybin activates a sub-type of serotonin receptor in the brain. “Our brains are hard-wired to have these kinds of experiences – these alterations of consciousness. We have endogenous chemicals in our brain. We have a little system that, when you tickle it, it produces these altered states that have been described as spiritual states, mystical states in different religious branches.

“They are defined by a sense of oneness – people feel that their separation between the personal ego and the outside world is sort of dissolved and they feel that they are part of some continuous energy or consciousness in the universe. Patients can feel sort of transported to a different dimension of reality, sort of like a waking dream.”

Some patients describe seeing images from their childhood and very commonly, scenes or images from a confrontation with cancer, he said. The doctors warn patients that it may happen and not to be scared, but to embrace it and pass through it, he said.

The commentators writing in the journal include two past presidents of the American Psychiatric Association, the past president of the European College of Neuropsychopharmacology, a previous deputy director of the Office of USA National Drug Control Policy and a previous head of the UK Medicines and Healthcare Regulatory Authority.

The journal editor, Professor David Nutt, was himself involved in a small trial of psilocybin in a dozen people with severe depression in the UK in May. The ten commentators in the journal, he writes in an editorial, “all essentially say the same thing: it’s time to take psychedelic treatments in psychiatry and oncology seriously, as we did in the 1950s and 1960s.”

Much more research needs to be done, he writes. “But the key point is that all agree we are now in an exciting new phase of psychedelic psychopharmacology that needs to be encouraged not impeded.”

The studies were funded by the Heffter Research Institute in the USA. “These findings, the most profound to date in the medical use of psilocybin, indicate it could be more effective at treating serious psychiatric diseases than traditional pharmaceutical approaches, and without having to take a medication every day,” said its medical director George Greer.

Magic mushroom ingredient psilocybin can lift depression, studies show